Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Delivery of Hypoxia Inducible Heme Oxygenase-1 Gene Using Dexamethasone Conjugated Polyethylenimine for Protection of Cardiomyocytes under Hypoxia

  • Kim, Hyun-Jung (Department of Bioengineering, College of Engineering, Hanyang University) ;
  • Kim, Hyun-Ah (Department of Bioengineering, College of Engineering, Hanyang University) ;
  • Choi, Joon-Sig (Department of Biochemistry, College of Natural Science, Chungnam National University) ;
  • Lee, Min-Hyung (Department of Bioengineering, College of Engineering, Hanyang University)
  • Published : 2009.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

Heme oxygenase-1 (HO-1) is an anti-inflammatory and anti-apoptotic protein and has been applied to various gene therapy researches. However, constitutive expression of HO-1 may induce deleterious side effects. In this research, hypoxia inducible HO-1 expression plasmid, pEpo-SV-HO-1, was constructed with the erythropoietin (epo) enhancer and simian virus 40 (SV40) promoter to avoid these unwanted side effects. Dexamethasone conjugated polyethylenimine (PEI-Dexa) was used as a gene carrier. It was previously reported that dexamethasone protected cardiomyocytes from apoptosis under hypoxia. In this research, PEI-Dexa reduced the caspase-3 level in hypoxic H9C2 cardiomyocytes as a derivative of dexamethasone, suggesting that PEI-Dexa is an anti-apoptotic reagent as well as a gene carrier. pEpo-SV-HO-1 was transfected to H9C2 cardiomyocytes using PEI-Dexa and the cells were incubated under normoxia or hypoxia. HO-1 expression was induced in the pEpo-SV-HO-1 transfected cells under hypoxia. In addition, cell viability under hypoxia was higher in the pEpo-SV-HO-1 transfected cells than the pEpo-SV-Luc transfected cells. Also, caspase-3 level was reduced in the pEpo-SV-HO-1 transfected cells under hypoxia. In addition to the anti-apoptotic effect of PEI-Dexa, hypoxia inducible HO-1 expression by pEpo-SVHO- 1 may be helpful to protect cardiomyocytes under hypoxia. Therefore, pEpo-SV-HO-1/PEI-Dexa complex may be useful for ischemic heart disease gene therapy.

Keywords

References

  1. Tongers, J.; Fiedler, B.; Konig, D.; Kempf, T.; Klein, G.; Heineke, J.; Kraft, T.; Gambaryan, S.; Lohmann, S. M.; Drexler, H.; Wollert, K. C. Cardiovasc. Res. 2004, 3, 545.
  2. Kacimi, R.; Chentoufi, J.; Honbo, N.; Long, C. S.; Karliner, J. S. Cardiovasc. Res. 2000, 1, 139.
  3. Takahashi, T.; Shimizu, H.; Morimatsu, H.; Inoue, K.; Akagi, R.; Morita, K.; Sassa, S. Mini. Rev. Med. Chem. 2007, 7, 745. https://doi.org/10.2174/138955707781024517
  4. Idriss, N. K.; Blann, A. D.; Lip, G. Y. J. Am. Coll. Cardiol. 2008, 12, 971.
  5. Abraham, N. G.; Kappas, A. Pharmacol. Rev. 2008, 1, 79.
  6. Yet, S. F.; Tian, R.; Layne, M. D.; Wang, Z. Y.; Maemura, K.; Solovyeva, M.; Ith, B.; Melo, L. G.; Zhang, L.; Ingwall, J. S.; Dzau, V. J.; Lee, M. E.; Perrella, M. A. Circ. Res. 2001, 2, 168.
  7. Hu, C. M.; Chen, Y. H.; Chiang, M. T.; Chau, L. Y. Circulation 2004, 3, 309.
  8. Foo, R. S.; Siow, R. C.; Brown, M. J.; Bennett, M. R. J. Cell. Physiol. 2006, 1, 1.
  9. Jin, Y.; Choi, A. M. Proc. Am. Thorac. Soc. 2005, 3, 232.
  10. Ryter, S. W.; Kim, H. P.; Nakahira, K.; Zuckerbraun, B. S.; Morse, D.; Choi, A. M. Antioxid. Redox. Signal 2007, 12, 2157.
  11. Pang, Q. F.; Zhou, Q. M.; Zeng, S.; Dou, L. D.; Ji, Y.; Zeng, Y. M. Chin. Med. J. (Engl) 2008, 17, 1688.
  12. Chen, C.; Wang, Y. L.; Wang, C. Y.; Zhang, Z. Z. Chin. J. Traumatol. 2008, 2, 78.
  13. Tang, Y. L.; Tang, Y.; Zhang, Y. C.; Qian, K.; Shen, L.; Phillips, M. I. Hypertension 2004, 4, 746.
  14. Tang, Y. L.; Qian, K.; Zhang, Y. C.; Shen, L.; Phillips, M. I. J. Cardiovasc. Pharmacol. Ther. 2005, 4, 251.
  15. Platt, J. L.; Nath, K. A. Nat. Med. 1998, 12, 1364.
  16. Bae, Y. M.; Choi, H.; Lee, S.; Kang, S. H.; Nam, K.; Kim, Y. T.; Park, J. S.; Lee, M.; Choi, J. S. Bioconjug. Chem. 2007, 6, 2029.
  17. Adcock, I. M.; Caramori, G. Immunol. Cell Biol. 2001, 4, 376.
  18. Shahin, V.; Albermann, L.; Schillers, H.; Kastrup, L.; Schafer, C.; Ludwig, Y.; Stock, C.; Oberleithner, H. J. Cell Physiol. 2005, 2, 591.
  19. Chen, Q. M.; Alexander, D.; Sun, H.; Xie, L.; Lin, Y.; Terrand, J.; Morrissy, S.; Purdom, S. Mol. Pharmacol. 2005, 6, 1861.
  20. Sun, L.; Chang, J.; Kirchhoff, S. R.; Knowlton, A. A. Am. J. Physiol. Heart Circ. Physiol. 2000, 4, H1091.
  21. Reeve, J. L.; Szegezdi, E.; Logue, S. E.; Chonghaile, T. N.; O'Brien, T.; Ritter, T.; Samali, A. J. Cell Mol. Med. 2007, 3, 509.
  22. Kim, H.; Kim, H. A.; Bae, Y. M.; Choi, J. S.; Lee, M. J. Gene Med. 2009, Published online, DOI: 10.1002/jgm. 1320.
  23. Deramaudt, T. B.; da Silva, J. L.; Remy, P.; Kappas, A.; Abraham, N. G. Proc. Soc. Exp. Biol. Med. 1999, 2, 185.
  24. Lee, J. W.; Bae, S. H.; Jeong, J. W.; Kim, S. H.; Kim, K. W. Exp. Mol. Med. 2004, 1, 1.
  25. Lee, M.; Bikram, M.; Oh, S.; Bull, D. A.; Kim, S. W. Pharm. Res. 2004, 5, 736.
  26. Lee, M.; Choi, D.; Choi, M. J.; Jeong, J. H.; Kim, W. J.; Oh, S.; Kim, Y. H.; Bull, D. A.; Kim, S. W. J. Control. Release 2006, 1, 113.
  27. Kim, H. A.; Kim, K.; Kim, S. W.; Lee, M. J. Control. Release 2007, 3, 218.
  28. Lee, M.; Rentz, J.; Bikram, M.; Han, S.; Bull, D. A.; Kim, S. W. Gene Ther. 2003, 18, 1535.
  29. Choi, J. S.; Lee, E. J.; Choi, Y. H.; Jeong, Y. J.; Park, J. S. Bioconjug. Chem. 1999, 1, 62.
  30. Choi, Y. H.; Liu, F.; Choi, J. S.; Kim, S. W.; Park, J. S. Hum. Gene Ther. 1999, 16, 2657.
  31. Choi, J. S.; Joo, D. K.; Kim, C. H.; Kim, K.; Park, J. S. J. Am. Chem. Soc. 2000, 474.
  32. Lee, J. H.; Lim, Y. B.; Choi, J. S.; Lee, Y.; Kim, T. I.; Kim, H. J.; Yoon, J. K.; Kim, K.; Park, J. S. Bioconjug. Chem. 2003, 6, 1214.
  33. Kim, T. I.; Seo, H. J.; Choi, J. S.; Jang, H. S.; Baek, J. U.; Kim, K.; Park, J. S. Biomacromolecules 2004, 6, 2487.
  34. Choi, J. S.; Nam, K.; Park, J. Y.; Kim, J. B.; Lee, J. K.; Park, J. S. J. Control. Release 2004, 3, 445.
  35. Kim, T. I.; Seo, H. J.; Choi, J. S.; Yoon, J. K.; Baek, J. U.; Kim, K.; Park, J. S. Bioconjug. Chem. 2005, 5, 1140.
  36. Kim, T. I.; Baek, J. U.; Yoon, J. K.; Choi, J. S.; Kim, K.; Park, J. S. Bioconjug. Chem. 2007, 2, 309.
  37. Kim, H. J.; Kwon, M. S.; Choi, J. S.; Kim, B. H.; Yoon, J. K.; Kim, K.; Park, J. S. Bioorg. Med. Chem. 2007, 4, 1708.
  38. Nam, H. Y.; Hahn, H. J.; Nam, K.; Choi, W. H.; Jeong, Y.; Kim, D. E.; Park, J. S. Int. J. Pharm. 2008, 1-2, 199.
  39. Nam, H. Y.; Nam, K.; Hahn, H. J.; Kim, B. H.; Lim, H. J.; Kim, H. J.; Choi, J. S.; Park, J. S. Biomaterials 2009, 4, 665.
  40. Chang, C. N.; Yang, J. T.; Lee, T. H.; Cheng, W. C.; Hsu, Y. H.; Wu, J. H. J. Clin. Neurosci. 2005, 6, 680.
  41. Malaeb, S. N.; Sadowska, G. B.; Stonestreet, B. S. Brain Res. 2007, 1160, 11. https://doi.org/10.1016/j.brainres.2007.05.043
  42. Godbey, W. T.; Wu, K. K.; Mikos, A. G. Biomaterials 2001, 5, 471.
  43. Lee, M. Bull. Korean Chem. Soc. 2007, 1, 95.

Cited by

  1. Delivery of Hypoxia-Inducible Heme Oxygenase-1 Gene for Site-Specific Gene Therapy in the Ischemic Stroke Animal Model vol.33, pp.9, 2016, https://doi.org/10.1007/s11095-016-1962-9
  2. Hydrophobic modifications of cationic polymers for gene delivery vol.35, pp.9, 2009, https://doi.org/10.1016/j.progpolymsci.2010.04.007
  3. Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect vol.20, pp.8, 2009, https://doi.org/10.3109/1061186x.2012.712127